BBIO – BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.BBIO
$38.61Name : BridgeBio Pharma, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,331,305,472.00
EPSttm : -3.56
BridgeBio Pharma, Inc.
$38.61
0.70%$0.27Float Short %
13.93
Margin Of Safety %
Put/Call OI Ratio
0.43
EPS Next Q Diff
0.35
EPS Last/This Y
0.54
EPS This/Next Y
0.29
Price
38.34
Target Price
60.53
Analyst Recom
1.37
Performance Q
18.96
Relative Volume
0.76
Beta
1.1
Ticker: BBIO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | BBIO | 35.8 | 0.59 | 0.16 | 111230 |
| 2025-05-08 | BBIO | 34.84 | 0.60 | 2.15 | 111078 |
| 2025-05-09 | BBIO | 34.17 | 0.59 | 0.88 | 110917 |
| 2025-05-12 | BBIO | 35.64 | 0.59 | 0.60 | 110865 |
| 2025-05-13 | BBIO | 33.25 | 0.60 | 0.26 | 112032 |
| 2025-05-14 | BBIO | 33.65 | 0.59 | 0.36 | 113217 |
| 2025-05-15 | BBIO | 33.73 | 0.58 | 0.02 | 113574 |
| 2025-05-16 | BBIO | 33.83 | 0.58 | 0.15 | 113493 |
| 2025-05-19 | BBIO | 33.68 | 0.39 | 0.14 | 70509 |
| 2025-05-20 | BBIO | 33.69 | 0.39 | 0.67 | 71173 |
| 2025-05-21 | BBIO | 32.82 | 0.39 | 0.51 | 71405 |
| 2025-05-22 | BBIO | 32.96 | 0.39 | 1.03 | 71564 |
| 2025-05-23 | BBIO | 33.34 | 0.39 | 1.17 | 71893 |
| 2025-05-27 | BBIO | 33.1 | 0.39 | 1.02 | 72049 |
| 2025-05-28 | BBIO | 32.25 | 0.40 | 0.26 | 72108 |
| 2025-05-29 | BBIO | 33.38 | 0.40 | 0.11 | 71944 |
| 2025-05-30 | BBIO | 34.24 | 0.40 | 0.06 | 72236 |
| 2025-06-02 | BBIO | 35.46 | 0.40 | 2.19 | 72505 |
| 2025-06-03 | BBIO | 37.52 | 0.40 | 0.85 | 72570 |
| 2025-06-04 | BBIO | 38.03 | 0.43 | 0.72 | 74610 |
| 2025-06-05 | BBIO | 38.33 | 0.43 | 0.01 | 75511 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | BBIO | 35.82 | 68.5 | 139.5 | -2.74 |
| 2025-05-08 | BBIO | 34.84 | 68.5 | 138.4 | -2.74 |
| 2025-05-09 | BBIO | 34.15 | 68.5 | 135.7 | -2.74 |
| 2025-05-12 | BBIO | 35.68 | 68.5 | 112.7 | -2.74 |
| 2025-05-13 | BBIO | 33.25 | 68.5 | 153.0 | -2.74 |
| 2025-05-14 | BBIO | 33.64 | 68.5 | 124.5 | -2.74 |
| 2025-05-15 | BBIO | 33.72 | 68.5 | 127.9 | -2.74 |
| 2025-05-16 | BBIO | 33.82 | 68.5 | 127.7 | -2.62 |
| 2025-05-19 | BBIO | 33.69 | 68.5 | 130.1 | -2.62 |
| 2025-05-20 | BBIO | 33.69 | 68.5 | 127.9 | -2.62 |
| 2025-05-21 | BBIO | 32.81 | 68.5 | 138.0 | -2.62 |
| 2025-05-22 | BBIO | 32.95 | 68.5 | 127.3 | -2.62 |
| 2025-05-23 | BBIO | 33.34 | 68.5 | 124.5 | -2.62 |
| 2025-05-27 | BBIO | 33.10 | 68.5 | 131.1 | -2.62 |
| 2025-05-28 | BBIO | 32.23 | 68.5 | 137.8 | -2.62 |
| 2025-05-29 | BBIO | 33.38 | 68.5 | 116.3 | -2.62 |
| 2025-05-30 | BBIO | 34.25 | 68.5 | 119.1 | -2.62 |
| 2025-06-02 | BBIO | 35.48 | 68.5 | 115.7 | -2.62 |
| 2025-06-03 | BBIO | 37.52 | 68.5 | 107.6 | -2.62 |
| 2025-06-04 | BBIO | 38.02 | 68.5 | 123.7 | -2.62 |
| 2025-06-05 | BBIO | 38.34 | 76.7 | 125.4 | -2.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | BBIO | -22.73 | -2.11 | 14.37 |
| 2025-05-08 | BBIO | -39.82 | -2.11 | 12.79 |
| 2025-05-09 | BBIO | -39.82 | -2.11 | 12.79 |
| 2025-05-12 | BBIO | -39.82 | -1.68 | 14.28 |
| 2025-05-13 | BBIO | -22.79 | -1.68 | 14.28 |
| 2025-05-14 | BBIO | -22.79 | -1.68 | 14.28 |
| 2025-05-15 | BBIO | -31.68 | -1.68 | 14.31 |
| 2025-05-16 | BBIO | -31.68 | -1.68 | 14.31 |
| 2025-05-19 | BBIO | -31.68 | 0.62 | 13.81 |
| 2025-05-20 | BBIO | -35.63 | 0.62 | 13.81 |
| 2025-05-21 | BBIO | -35.73 | 0.62 | 13.81 |
| 2025-05-22 | BBIO | -35.73 | 0.62 | 13.81 |
| 2025-05-23 | BBIO | -35.73 | 0.62 | 13.81 |
| 2025-05-27 | BBIO | -35.73 | 4.50 | 13.80 |
| 2025-05-28 | BBIO | -35.81 | 4.50 | 13.93 |
| 2025-05-29 | BBIO | -35.81 | 4.50 | 13.93 |
| 2025-05-30 | BBIO | -35.81 | 4.50 | 13.93 |
| 2025-06-02 | BBIO | -35.81 | 4.76 | 13.93 |
| 2025-06-03 | BBIO | -35.81 | 4.76 | 13.93 |
| 2025-06-04 | BBIO | -35.81 | 4.76 | 13.93 |
| 2025-06-05 | BBIO | -35.81 | 4.76 | 13.93 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.88
Avg. EPS Est. Current Quarter
-0.23
Avg. EPS Est. Next Quarter
-0.53
Insider Transactions
-35.81
Institutional Transactions
4.76
Beta
1.1
Average Sales Estimate Current Quarter
100
Average Sales Estimate Next Quarter
89
Fair Value
Quality Score
25
Growth Score
45
Sentiment Score
96
Actual DrawDown %
47.8
Max Drawdown 5-Year %
-92.8
Target Price
60.53
P/E
Forward P/E
PEG
P/S
57.13
P/B
P/Free Cash Flow
EPS
-3.53
Average EPS Est. Cur. Y
-2.34
EPS Next Y. (Est.)
-2.04
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-524.25
Relative Volume
0.76
Return on Equity vs Sector %
16.5
Return on Equity vs Industry %
34.4
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.4
EBIT Estimation
125.4
BridgeBio Pharma, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 725
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
stock quote shares BBIO – BridgeBio Pharma, Inc. Stock Price stock today
news today BBIO – BridgeBio Pharma, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BBIO – BridgeBio Pharma, Inc. yahoo finance google finance
stock history BBIO – BridgeBio Pharma, Inc. invest stock market
stock prices BBIO premarket after hours
ticker BBIO fair value insiders trading